The near-term growth has been weighed down by pharma destocking, project delays of 2-3 quarters at NJ Bio due to slower biotech funding, and extended CMC timelines from partners.
The near-term growth has been weighed down by pharma destocking, project delays of 2-3 quarters at NJ Bio due to slower biotech funding, and extended CMC timelines from partners.